Allscripts (Nasdaq: MDRX) beat estimates by one cent last quarter and investors are hoping it can beat them again. The company will unveil its latest earnings on Thursday, Feb. 16. Allscripts is a provider of clinical software, services, information, and connectivity solutions.

What analysts say:

  • Buy, sell, or hold?: Analysts strongly back Allscripts, with 18 of 21 rating it a buy and the remainder rating it a hold. Analysts like Allscripts better than competitor athenahealth overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
  • Revenue Forecasts: On average, analysts predict $379.6 million in revenue this quarter. That would represent a rise of 12.6% from the year-ago quarter.
  • Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.21 per share. Estimates range from $0.19 to $0.23.

What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 97.7% assigning it an "outperform" rating. Most of the community is in line with the All-Stars, with 95.2% awarding it a rating of "outperform." Fools feel positively about Allscripts and haven't been shy with their opinions lately, logging 223 posts in the past 30 days. Even with a robust four out of five stars, Allscripts' CAPS rating falls a little short of the community's upbeat outlook.

Management:
The company's gross margin shrank by 673.9 percentage points in the last quarter. Revenue fell 7704.9% while cost of sales rose 572% to $201.8 million from a year earlier.

For all our Allscripts-specific analysis, including earnings and beyond, add Allscripts to My Watchlist.